* Evolent Health Inc EVH.N EVH is expected to show a
rise in
quarterly revenue when it reports results on November 2.
* The Arlington Virginia-based company is expected to
report a
44.4% increase in revenue to $509.24 million from $352.59
million a year ago, according to the mean estimate from 10
analysts, based on LSEG data. The company's guidance on August 2
2023, for the period ended September 30, was for revenue between
$500.00 million and $520.00 million.
* Refinitiv's mean analyst estimate for Evolent Health Inc
is for
earnings of 7 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Evolent
Health
Inc is $46, above its last closing price of $24.43.
The company's guidance on August 2 2023 for the period ended
September 30 was for Earnings before Interest, Taxes,
Depreciation and Amortization of between USD500 million and
USD47 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2023 0.12 0.11 0.14 Beat 24
Mar. 31 2023 0.21 0.20 0.21 Beat 3.7
Dec. 31 2022 0.20 0.16 0.10 Missed -39.1
Sep. 30 2022 0.13 0.12 0.59 Beat 397.6
Jun. 0.05 0.05 0.10 Beat 105.9
30 2022
Mar. 31 2022 0.00 0.00 0.12 Beat 6,100
Dec. 31 2021 0.00 0.01 0.08 Beat 860.4
Sep. 30 2021 -0.02 -0.03 -0.03 Met 8.7
This summary was machine generated November 1 at 02:44 GMT. All
figures in US dollars unless otherwise stated